AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

{
  "signal_id": "423d63f1-a5dc-8859-28ec-a4736325f999",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-22T06:00:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-children-with-active-polyarticular-juvenile-idiopathic-arthritis-302885190.html",
    "title": "AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis",
    "excerpt": "NORTH CHICAGO, Ill. , Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. 1 \"The European Commission's approval of RINVOQ for pJIA expands the treatment options available to pediatric patients and their families, offering the potential for remission, improvements in pain and physical function,\" said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. \"RINVOQ's new indication continues to build on our differentiated immunology portfolio with breadth and depth across therapeutic areas and patient populations.\" Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood and is estimated to impact approximately 126,000 children in Europe. 3 pJIA is a subtype of JIA and is characterized by inflammation in five or more joints – including the small joints of the hands and...",
    "product": "RINVOQ",
    "summary": "AbbVie's drug RINVOQ (upadacitinib) received approval from the European Commission for treating active polyarticular juvenile idiopathic arthritis in patients aged two and older.",
    "location": "Europe",
    "planning": false,
    "confidence": 1,
    "product_data": {
      "name": "RINVOQ",
      "full_text": "RINVOQ ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-22T06:00:00Z",
    "location_data": [
      {
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-22",
    "article_sentence": "AbbVie (NYSE: ABBV ) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs)."
  }
}

curl https://signals.autobound.ai/v1/signals/423d63f1-a5dc-8859-28ec-a4736325f999 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'